EligibleTrials

Neurovascular Transduction During Exercise in Chronic Kidney Disease

Recruiting · NCT02947750 · Interventional (participants receive a specific treatment) · Lead sponsor: Emory University

View the official record on ClinicalTrials.gov →
HypertensionChronic kidney disease

Interventions studied

6R-BH46R-BH4 placeboExercise trainingFolic acidHistidine and beta-alanine placeboHistidine and beta-alanine supplementationStretching

What this trial is about

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

6 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.